drug_type
RELEVANT_DRUG
intervention_type
Biological (cellular vaccine)
drug_description
An autologous monocyte-derived dendritic cell vaccine pulsed with Epstein–Barr virus (EBV)-associated antigens. The ex vivo–generated dendritic cells present EBV antigens via MHC I/II to prime and expand EBV-specific CD8+ cytotoxic and CD4+ helper T cells, enhancing IFN-γ production and perforin/granzyme-mediated killing of EBV-positive lymphoma cells.
nci_thesaurus_concept_id
C200792
nci_thesaurus_definition
A cell-based cancer vaccine composed of autologous monocyte-derived dendritic cells (DCs) pulsed with allogeneic Epstein-Barr virus (EBV)-transformed B-lymphoblastoid cell line (BLCL) lysate, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, DCs are loaded with allogeneic EBV-transformed BLCL lysate. Upon re-administration of the allogeneic EBV-transformed BLCL lysate-pulsed autologous DC vaccine KSD-101, the immune system is exposed to EBV-specific antigens, which stimulates the induction of a specific cytotoxic T-lymphocyte (CTL) response against EBV-positive tumor cells or EBV-infected cells. This results in cell lysis and inhibition of cancer cell proliferation. EBV, a ubiquitous human herpes virus, is associated with various malignancies.
drug_mesh_term
Dendritic Cell Vaccine
drug_category
DC VACCINE
drug_class
Vaccine
drug_delivery_route
Not specified
drug_mechanism_of_action
Autologous monocyte-derived dendritic cells pulsed with EBV antigens present peptides via MHC I/II to prime and expand EBV-specific CD8+ cytotoxic and CD4+ helper T cells, enhancing IFN-gamma production and perforin/granzyme-mediated killing of EBV-positive lymphoma cells.
drug_name
KSD-101
nct_id_drug_ref
NCT05882305